<div id="readability-page-1"><p>Evercore ISI analyst Cory Kasimov maintained a Buy rating on Edgewise Therapeutics yesterday and set a price target of $30.00. The company’s shares closed yesterday at $22.26.</p><h3>Meet Your ETF AI Analyst</h3><ul><li> Discover how TipRanks' <i>ETF</i> AI Analyst  can help you make smarter investment decisions </li><li>   Explore ETFs TipRanks' users love  and see what insights the <b><i>ETF</i> AI Analyst</b> reveals about the ones you follow.</li></ul> <p>According to TipRanks, Kasimov is a 5-star analyst with an average return of <span>16.6%</span> and a 55.60% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Immunome, and Alnylam Pharma.</p> <p>Edgewise Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $37.00, a 66.22% upside from current levels. In a report released on November 14, J.P. Morgan also maintained a Buy rating on the stock with a $34.00 price target.</p></div>

EWTX

<p>Evercore ISI analyst Cory Kasimov maintains a Buy rating on Edgewise Therapeutics with a $30 price target. Shares closed at $22.26. Kasimov, a 5-star analyst, has a 16.6% average return. Edgewise has a Strong Buy consensus with a $37 price target, indicating a 66.22% upside. J.P. Morgan also rates it Buy with a $34 target.</p>

Edgewise Therapeutics (EWTX) Gets a Buy from Evercore ISI